Nicotinic acid as a lipid-modifying drug - A review

Atherosclerosis Supplements

Volumn 14, Issue 1, 2013, Pages 7-13

  Julius, U ^a,b   Fischer, S ^a,b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b not available   (Germany)

Author keywords

Hyperlipidemia; Indications; Intervention studies; Mechanisms of action; Nicotinic acid; Side effects

Indexed keywords

ACIPIMOX; ATORVASTATIN; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT PLUS NICOTINIC ACID; NICOTINIC ACID; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ARTICLE; ATHEROGENESIS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; DIARRHEA; DOSE RESPONSE; DRUG EFFECT; DRUG HYPERSENSITIVITY; FLUSHING; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; HYPOTENSION; LIPOPROTEIN METABOLISM; MORBIDITY; MORTALITY; NAUSEA; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL; TREATMENT INDICATION; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; VOMITING;

EID: 84872953730     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2012.10.036     Document Type: Article

References (41)

1. Sampson U.K., Fazio S., Linton M.F. Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep 2012, 14(1):1-10.
2. Yadav R., France M., Younis N., et al. Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety. Expert Opin Pharmacother 2012, 13(9):1345-1362.
3. Lukasova M., Hanson J., Tunaru S., Offermanns S. Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials. Trends Pharmacol Sci 2011, 32(12):700-707.
4. Seed M., O'Connor B., Perombelon N., O'Donnell M., Reaveley D., Knight B.L. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. Atherosclerosis 1993, 101(1):61-68.
5. Digby J.E., Martinez F., Jefferson A., Ruparelia N., Chai J., Wamil M., et al. Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. Arterioscler Thromb Vasc Biol 2012, 32(3):669-676.
6. Wu B.J., Yan L., Charlton F., Witting P., Barter P.J., Rye K.A. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler Thromb Vasc Biol 2010, 30(5):968-975.
7. Wu B.J., Chen K., Barter P.J., Rye K.A. Niacin inhibits vascular inflammation via the induction of heme oxygenase-1. Circulation 2012, 125(1):150-158.
8. Kang I., Kim S.W., Youn J.H. Effects of nicotinic acid on gene expression: potential mechanisms and implications for wanted and unwanted effects of the lipid-lowering drug. J Clin Endocrinol Metab 2011, 96(10):3048-3055.
9. Ng C.F., Lee C.P., Ho A.L., Lee V.W. Effect of niacin on erectile function in men suffering erectile dysfunction and dyslipidemia. J Sex Med 2011, 8(10):2883-2893.
10. Lupachyk S., Watcho P., Hasanova N., Julius U., Obrosova I.G. Triglyceride, nonesterified fatty acids, and prediabetic neuropathy: role for oxidative-nitrosative stress. Free Radic Biol Med 2012, 52(8):1255-1263.
11. Bostom A.G., Maclean A.A., Maccubbin D., Tipping D., Giezek H., Hanlon W.A. Extended-release niacin/laropiprant lowers serum phosphorus concentrations in patients with type 2 diabetes. J Clin Lipidol 2011, 5(4):281-287.
12. Rajanna V., Campbell K.B., Leimberger J., Mohanty B.D., Guyton J.R. Elevation of fasting morning glucose relative to hemoglobin A1c in normoglycemic patients treated with niacin and with statins. J Clin Lipidol 2012, 6(2):168-173.
13. Chen F, Maccubbin D, Yan L, Sirah W, Chen E, Sisk CM, et al. Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. Int J Cardiol, http://dx.doi.org/10.1016/j.ijcard.2011.12.103.
14. Markel A. The resurgence of niacin: from nicotinic acid to niaspan/laropiprant. Isr Med Assoc J 2011, 13(6):368-374.
15. Guyton J.R., Fazio S., Adewale A.J., et al. Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial. Diabetes Care 2012, 35(4):857-860.
16. Hochholzer W., Berg D.D., Giugliano R.P. The facts behind niacin. Ther Adv Cardiovasc Dis 2011, 5(5):227-240.
17. Yadav R., Kwok S., Ammori B.J., Issa B., Soran H. Safety and tolerability of extended-release niacin with laropiprant. Expert Opin Drug Saf 2012, 11(1):151-159.
18. Vosper H. Extended release niacin-laropiprant in patients with hypercholesterolemia or mixed dyslipidemias improves clinical parameters. Clin Med Insights Cardiol 2011, 5:85-101.
19. Morgan J.M., Capuzzi D.M., Guyton J.R. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 1998, 82(12A):29U-34U.
20. Guyton J.R., Blazing M.A., Hagar J., et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med 2000, 160(8):1177-1184.
21. Insull W., Toth P.P., Superko H.R., et al. Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. Vasc Health Risk Manag 2010, 6:1065-1075.
22. Toth P.P., Thakker K.M., Jiang P., Padley R.J. Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy. Vasc Health Risk Manag 2012, 8:39-44.
23. Maccubbin D.L., Chen F., Anderson J.W., Sirah W., McCrary S.C., Kher U., et al. Effectiveness and safety of laropiprant on niacin-induced flushing. Am J Cardiol 2012, 110(6):817-822.
24. Maclean A. Efficacy and safety of extended-release niacin/laropiprant in patients wit type 2 diabetes mellitus. Br J Cardiol 2012, 18:37-45.
25. Chapman M.J., Redfern J.S., McGovern M.E., Giral P. Optimal pharmacotherapy to combat the atherogenic lipid triad. Curr Opin Cardiol 2011, 26(5):403-411.
26. Michos E.D., Sibley C.T., Baer J.T., Blaha M.J., Blumenthal R.S. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: impact on global health outcomes) trial with previous surrogate endpoint trials. J Am Coll Cardiol 2012, 59(23):2058-2064.
27. Lee K., Ahn T.H., Kang W.C., Han S.H., Choi I.S., Shin E.K. The effects of statin and niacin on plaque stability, plaque regression, inflammation and oxidative stress in patients with mild to moderate coronary artery stenosis. Korean Circ J 2011, 41(11):641-648.
28. Lee J.M., Robson M.D., Yu L.M., Shirodaria C.C., Cunnington C., Kylintireas I., et al. Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009, 54(19):1787-1794.
29. Taylor A.J., Villines T.C., Stanek E.J., et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361(22):2113-2122.
30. Bruckert E., Labreuche J., Amarenco P. Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. Atherosclerosis 2010, 210(2):353-361.
31. Giugliano R.P. Niacin at 56 years of age-time for an early retirement?. N Engl J Med 2011, 365(24):2318-2320.
32. Canner P.L., Berge K.G., Wenger N.K., Stamler J., Friedman L., Prineas R.J., et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986, 8(6):1245-1255.
33. Boden W.E., Probstfield J.L., Anderson T., et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365(24):2255-2267.
34. Viljoen A., Wierzbicki A.S. Safety and efficacy of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia. Drug Health Patient Saf 2010, 2:61-71.
35. Parhofer K.G. Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia. Vasc Health Risk Manag 2009, 5:901-908.
36. Reiner Z., Catapano A.L., De Backer G., et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32(14):1769-1818.
37. Shanes J.G. A review of the rationale for additional therapeutic interventions to attain lower LDL-C when statin therapy is not enough. Curr Atheroscler Rep 2012, 14(1):33-40.
38. McKenney J.M. Combination treatment with atorvastatin plus niacin provides effective control of complex dyslipidemias: a literature review. Postgrad Med 2012, 124(1):7-20.
39. Villines T.C., Kim A.S., Gore R.S., Taylor A.J. Niacin: the evidence, clinical use, and future directions. Curr Atheroscler Rep 2012, 14(1):49-59.
40. Michailov G.V., Davies G.M., Krobot K.J. Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany. Eur J Health Econ 2012, 13(3):365-374.
41. Chapman M.J., Assmann G., Fruchart J.C., Shepherd J., Sirtori C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid - a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004, 20(8):1253-1268.